US5656295A
(en)
*
|
1991-11-27 |
1997-08-12 |
Euro-Celtique, S.A. |
Controlled release oxycodone compositions
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5580578A
(en)
*
|
1992-01-27 |
1996-12-03 |
Euro-Celtique, S.A. |
Controlled release formulations coated with aqueous dispersions of acrylic polymers
|
US5681585A
(en)
|
1991-12-24 |
1997-10-28 |
Euro-Celtique, S.A. |
Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5968551A
(en)
*
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
IL119660A
(en)
|
1993-05-10 |
2002-09-12 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP0647448A1
(en)
*
|
1993-10-07 |
1995-04-12 |
Euroceltique S.A. |
Orally administrable opioid formulations having extended duration of effect
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US6210714B1
(en)
*
|
1993-11-23 |
2001-04-03 |
Euro-Celtique S.A. |
Immediate release tablet cores of acetaminophen having sustained-release coating
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
US5558879A
(en)
*
|
1995-04-28 |
1996-09-24 |
Andrx Pharmaceuticals, Inc. |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
|
GB9519363D0
(en)
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
DK0888111T3
(da)
*
|
1996-03-08 |
2003-09-22 |
Nycomed Danmark As |
Modified-release-dosispræparat med multiple enheder
|
WO1997045091A2
(en)
*
|
1996-05-31 |
1997-12-04 |
Euro-Celtique, S.A. |
Sustained release oxycodone formulations with no fed/fast effect
|
JPH1050306A
(ja)
*
|
1996-07-31 |
1998-02-20 |
Toyota Autom Loom Works Ltd |
水素吸蔵合金電極の製造方法
|
DE19710008A1
(de)
*
|
1997-03-12 |
1998-09-17 |
Basf Ag |
Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
|
RS49982B
(sr)
*
|
1997-09-17 |
2008-09-29 |
Euro-Celtique S.A., |
Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
KR100417489B1
(ko)
|
1997-12-22 |
2004-02-05 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 효능제/길항제 혼합물
|
US6228863B1
(en)
*
|
1997-12-22 |
2001-05-08 |
Euro-Celtique S.A. |
Method of preventing abuse of opioid dosage forms
|
EP0955048A1
(en)
*
|
1998-03-12 |
1999-11-10 |
Akzo Nobel N.V. |
Making dosage units using low shear granulation
|
IL128818A0
(en)
*
|
1998-03-12 |
2000-01-31 |
Akzo Nobel Nv |
Making dosage units using low shear granulation
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
HU230828B1
(en)
|
1999-10-29 |
2018-08-28 |
Euro Celtique Sa |
Controlled release hydrocodone formulations
|
AU2277101A
(en)
*
|
1999-12-20 |
2001-07-03 |
Schering Corporation |
Stable extended release oral dosage composition
|
WO2001045676A2
(en)
*
|
1999-12-20 |
2001-06-28 |
Schering Corporation |
Extended release oral dosage composition
|
DK1299104T3
(da)
|
2000-02-08 |
2009-08-03 |
Euro Celtique Sa |
Orale opioidagonistformuleringer sikret mod forfalskning
|
WO2002036099A1
(en)
|
2000-10-30 |
2002-05-10 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
US20030065002A1
(en)
|
2001-05-11 |
2003-04-03 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
JP2004534056A
(ja)
*
|
2001-06-08 |
2004-11-11 |
エンドー ファーマシューティカルズ, インコーポレイティド |
アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
|
BR0210855A
(pt)
*
|
2001-07-06 |
2006-10-24 |
Penwest Pharmaceuticals Compan |
Método de fabricação de formulações de liberação prolongada
|
CA2452871C
(en)
|
2001-07-06 |
2011-10-04 |
Endo Pharmaceuticals, Inc. |
Oxymorphone controlled release formulations
|
US8329216B2
(en)
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
JP4256259B2
(ja)
|
2001-07-18 |
2009-04-22 |
ユーロ−セルティーク エス.エイ. |
オキシコドン及びナロキソンの医薬配合物
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
AU2002323032B2
(en)
|
2001-08-06 |
2005-02-24 |
Euro-Celtique S.A. |
Opioid agonist formulations with releasable and sequestered antagonist
|
AU2002321879A1
(en)
*
|
2001-08-06 |
2003-03-03 |
Thomas Gruber |
Pharmaceutical formulation containing dye
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20040253310A1
(en)
|
2001-09-21 |
2004-12-16 |
Gina Fischer |
Morphine polymer release system
|
WO2003024429A1
(en)
|
2001-09-21 |
2003-03-27 |
Egalet A/S |
Polymer release system
|
AU2002337686B2
(en)
*
|
2001-09-26 |
2008-05-15 |
Penwest Pharmaceuticals Company |
Opioid formulations having reduced potential for abuse
|
PE20030527A1
(es)
|
2001-10-24 |
2003-07-26 |
Gruenenthal Chemie |
Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
|
PT1484056E
(pt)
*
|
2002-02-21 |
2013-10-14 |
Otsuka Pharma Co Ltd |
Preparações de libertação prolongada e processo para a produção das mesmas
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
CA2708900C
(en)
|
2002-04-05 |
2019-06-04 |
Purdue Pharma |
Pharmaceutical preparation containing oxycodone and naloxone
|
US20030224051A1
(en)
*
|
2002-05-31 |
2003-12-04 |
Fink Tracy A. |
Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
|
US20050106249A1
(en)
*
|
2002-04-29 |
2005-05-19 |
Stephen Hwang |
Once-a-day, oral, controlled-release, oxycodone dosage forms
|
BR0309620A
(pt)
*
|
2002-04-29 |
2005-03-15 |
Alza Corp |
Métodos e formas de dosagem para liberação controlada de oxicodona
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
US20040001889A1
(en)
|
2002-06-25 |
2004-01-01 |
Guohua Chen |
Short duration depot formulations
|
US10004729B2
(en)
|
2002-07-05 |
2018-06-26 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US20040058946A1
(en)
*
|
2002-07-05 |
2004-03-25 |
Buchwald Stephen L. |
Abuse-resistant prodrugs of oxycodone and other pharmaceuticals
|
CA2491572C
(en)
*
|
2002-07-05 |
2010-03-23 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opiods and other drugs
|
US8840928B2
(en)
|
2002-07-05 |
2014-09-23 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US8557291B2
(en)
|
2002-07-05 |
2013-10-15 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
|
US7168140B2
(en)
*
|
2002-08-08 |
2007-01-30 |
Milliken & Company |
Flame resistant fabrics with improved aesthetics and comfort, and method of making same
|
CN100439373C
(zh)
*
|
2002-08-15 |
2008-12-03 |
诺拉姆科有限公司 |
羟考酮盐酸盐多晶型物
|
AU2003272601B2
(en)
*
|
2002-09-20 |
2009-05-07 |
Alpharma Pharmaceuticals, Llc |
Sustained-release opioid formulations and methods of use
|
AU2003270778B2
(en)
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
US20040110781A1
(en)
*
|
2002-12-05 |
2004-06-10 |
Harmon Troy M. |
Pharmaceutical compositions containing indistinguishable drug components
|
US9107804B2
(en)
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
JP4865330B2
(ja)
*
|
2002-12-13 |
2012-02-01 |
デュレクト コーポレーション |
経口ドラッグデリバリーシステム
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
ATE454169T1
(de)
|
2003-03-13 |
2010-01-15 |
Controlled Chemicals Inc |
Oxycodon- konjugate mit niedrigerem missbrauch- potential und ausgedehnter tätigkeitsdauer
|
EP1782834A3
(en)
*
|
2003-03-13 |
2007-08-01 |
Controlled Chemicals, Inc. |
Oxycodone conjugates with lower abuse potential and extended duration of action
|
EP1610767B1
(en)
|
2003-03-26 |
2011-01-19 |
Egalet A/S |
Morphine controlled release system
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
JP5501553B2
(ja)
|
2003-04-21 |
2014-05-21 |
ユーロ−セルティーク エス.エイ. |
同時押出逆作用剤粒子を含有する改変防止剤形およびその製造工程
|
US8158149B2
(en)
*
|
2004-05-12 |
2012-04-17 |
Chelsea Therapeutics, Inc. |
Threo-DOPS controlled release formulation
|
WO2004100929A1
(en)
|
2003-05-12 |
2004-11-25 |
Synergia Pharma, Inc. |
Threo-dops controlled release formulation
|
TWI357815B
(en)
*
|
2003-06-27 |
2012-02-11 |
Euro Celtique Sa |
Multiparticulates
|
US20060165790A1
(en)
*
|
2003-06-27 |
2006-07-27 |
Malcolm Walden |
Multiparticulates
|
DK2279729T3
(da)
*
|
2003-07-17 |
2016-11-28 |
Banner Life Sciences Llc |
Præparater med kontrolleret frigivelse
|
DE10336400A1
(de)
*
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
US8075872B2
(en)
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE102004020220A1
(de)
*
|
2004-04-22 |
2005-11-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
DE102005005446A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
ATE365545T1
(de)
*
|
2003-08-06 |
2007-07-15 |
Gruenenthal Gmbh |
Gegen missbrauch gesicherte darreichungsform
|
US20050053659A1
(en)
*
|
2003-09-10 |
2005-03-10 |
Pace Gary W. |
Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness
|
CA2541371C
(en)
*
|
2003-10-03 |
2014-12-16 |
Atul M. Mehta |
Extended release formulations of opioids and method of use thereof
|
US7201920B2
(en)
|
2003-11-26 |
2007-04-10 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of opioid containing dosage forms
|
US8883204B2
(en)
|
2003-12-09 |
2014-11-11 |
Purdue Pharma L.P. |
Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same
|
US20070269505A1
(en)
*
|
2003-12-09 |
2007-11-22 |
Flath Robert P |
Tamper Resistant Co-Extruded Dosage Form Containing An Active Agent And An Adverse Agent And Process Of Making Same
|
GB0403098D0
(en)
|
2004-02-12 |
2004-03-17 |
Euro Celtique Sa |
Extrusion
|
TWI350762B
(en)
|
2004-02-12 |
2011-10-21 |
Euro Celtique Sa |
Particulates
|
TW201509943A
(zh)
|
2004-03-30 |
2015-03-16 |
Euro Celtique Sa |
含有小於25ppm14-羥可待因酮之羥可酮鹽酸鹽之組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
|
DE602005012244D1
(de)
*
|
2004-03-30 |
2009-02-26 |
Euro Celtique Sa |
Manipulationssichere dosierform mit einem adsorbens und einem adversen mittel
|
US20050226929A1
(en)
*
|
2004-04-12 |
2005-10-13 |
Jianbo Xie |
Controlled release opioid analgesic formulation
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
US20070224269A1
(en)
*
|
2004-06-10 |
2007-09-27 |
Rubino Orapin P |
Controlled Release Pharmaceutical Formulation
|
PT1765292T
(pt)
|
2004-06-12 |
2017-12-29 |
Collegium Pharmaceutical Inc |
Formulações de fármacos dissuasoras de abuso
|
DE102004032049A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
DE102004032103A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
GB2418854B
(en)
*
|
2004-08-31 |
2009-12-23 |
Euro Celtique Sa |
Multiparticulates
|
BRPI0515600A
(pt)
*
|
2004-09-01 |
2008-07-29 |
Euro Celtique Sa |
formas farmacêuticas opióides tendo cmédia e auc em estado estável proporcionais à dose e cmax de dose única inferior ao proporcional à dose
|
ES2378671T3
(es)
|
2004-09-17 |
2012-04-16 |
Durect Corporation |
Composición anestésica local prolongada que contiene SAIB
|
US20080152595A1
(en)
*
|
2004-11-24 |
2008-06-26 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse of orally administered pharmaceutical products
|
JP2008525313A
(ja)
|
2004-12-27 |
2008-07-17 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
抗痴呆薬の安定化方法
|
US20060280789A1
(en)
*
|
2004-12-27 |
2006-12-14 |
Eisai Research Institute |
Sustained release formulations
|
US20090208579A1
(en)
*
|
2004-12-27 |
2009-08-20 |
Eisai R & D Management Co., Ltd. |
Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
|
EP2319499A1
(en)
|
2005-01-28 |
2011-05-11 |
Euro-Celtique S.A. |
Alcohol resistant dosage forms
|
DE102005005449A1
(de)
*
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
US20060281775A1
(en)
*
|
2005-06-14 |
2006-12-14 |
Applied Pharmacy Services, Inc. |
Two-component pharmaceutical composition for the treatment of pain
|
RU2408368C2
(ru)
|
2005-06-27 |
2011-01-10 |
Биовэйл Лэборэториз Интернэшнл С.Р.Л. |
Препараты соли бупропиона с модифицированным высвобождением
|
US20070027105A1
(en)
|
2005-07-26 |
2007-02-01 |
Alza Corporation |
Peroxide removal from drug delivery vehicle
|
EP1849460A3
(en)
*
|
2005-10-31 |
2007-11-14 |
ALZA Corporation |
Methods of reducing alcohol-induced dose dumping for opioid sustained release oral dosage forms
|
CN1957909B
(zh)
*
|
2005-10-31 |
2013-09-11 |
阿尔扎公司 |
降低鸦片样物质持续释放口服剂型的由醇诱导的剂量突然释放的方法
|
PL116330U1
(en)
*
|
2005-10-31 |
2007-04-02 |
Alza Corp |
Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
|
US20100172989A1
(en)
*
|
2006-01-21 |
2010-07-08 |
Abbott Laboratories |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
US20090022798A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Abbott Gmbh & Co. Kg |
Formulations of nonopioid and confined opioid analgesics
|
US20090317355A1
(en)
*
|
2006-01-21 |
2009-12-24 |
Abbott Gmbh & Co. Kg, |
Abuse resistant melt extruded formulation having reduced alcohol interaction
|
DK3095447T3
(da)
|
2006-02-03 |
2022-01-31 |
Opko Renal Llc |
Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
WO2007108109A1
(ja)
*
|
2006-03-15 |
2007-09-27 |
Johoku Chemical Co., Ltd |
安定化されたポリオレフィン系樹脂およびポリオレフィン系樹脂の安定化方法
|
US20070281016A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and surfactant
|
US20070281017A1
(en)
*
|
2006-06-06 |
2007-12-06 |
Endo Pharmaceuticals Inc., A Delaware Corporation |
Sustained release oxycodone composition with acrylic polymer and metal hydroxide
|
US20080069891A1
(en)
*
|
2006-09-15 |
2008-03-20 |
Cima Labs, Inc. |
Abuse resistant drug formulation
|
MX2008016372A
(es)
|
2006-06-19 |
2009-05-28 |
Alpharma Inc |
Composiciones farmaceuticas.
|
EP3659608A1
(en)
|
2006-06-21 |
2020-06-03 |
Opko Ireland Global Holdings, Ltd. |
Therapy using vitamin d repletion agent and vitamin d hormone replacement agent
|
EP2046285B1
(en)
*
|
2006-08-04 |
2018-02-21 |
Ethypharm |
Granule and orally disintegrating tablet comprising oxycodone
|
CA2661302A1
(en)
*
|
2006-08-16 |
2008-02-21 |
Auspex Pharmaceuticals, Inc. |
Preparation and utility of opioid analgesics
|
SA07280459B1
(ar)
|
2006-08-25 |
2011-07-20 |
بيورديو فارما إل. بي. |
أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
|
US8445018B2
(en)
|
2006-09-15 |
2013-05-21 |
Cima Labs Inc. |
Abuse resistant drug formulation
|
EP2124556B1
(en)
|
2006-10-09 |
2014-09-03 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
EP2117521B1
(en)
|
2006-11-03 |
2012-06-27 |
Durect Corporation |
Transdermal delivery systems comprising bupivacaine
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
CN104257667B
(zh)
|
2007-04-25 |
2019-06-04 |
欧普科Ip 控股Ii 有限公司 |
治疗维生素d不足和缺乏、继发性甲状旁腺功能亢进症和维生素d-响应疾病的方法和组合物
|
US20100144684A1
(en)
|
2007-04-25 |
2010-06-10 |
Proventiv Therapeutics, Inc. |
Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease
|
EP2481400B1
(en)
|
2007-04-25 |
2014-06-18 |
Cytochroma Inc. |
Oral controlled release compositions comprising vitamin D compound and waxy carrier
|
US8202542B1
(en)
|
2007-05-31 |
2012-06-19 |
Tris Pharma |
Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
|
CA2687192C
(en)
|
2007-06-04 |
2015-11-24 |
Egalet A/S |
Controlled release pharmaceutical compositions for prolonged effect
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
US20080318993A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Hepatic Impairment
|
US20080318994A1
(en)
*
|
2007-06-21 |
2008-12-25 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instruction on Dosing for Renal Impairment
|
PL2200593T3
(pl)
*
|
2007-09-13 |
2017-02-28 |
Cima Labs Inc. |
Preparat leku odporny na nadużywanie
|
ES2337935T3
(es)
|
2007-11-09 |
2010-04-30 |
Acino Pharma Ag |
Comprimidos de accion retardada con hidromorfona.
|
WO2009088414A2
(en)
*
|
2007-12-06 |
2009-07-16 |
Durect Corporation |
Oral pharmaceutical dosage forms
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
CA2709992A1
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Abuse resistant pharmaceutical compositions of opiod agonists
|
CA2905541C
(en)
|
2008-01-09 |
2020-02-11 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
RU2493830C2
(ru)
*
|
2008-01-25 |
2013-09-27 |
Грюненталь Гмбх |
Лекарственная форма
|
US20090246276A1
(en)
|
2008-01-28 |
2009-10-01 |
Graham Jackson |
Pharmaceutical Compositions
|
US9226907B2
(en)
|
2008-02-01 |
2016-01-05 |
Abbvie Inc. |
Extended release hydrocodone acetaminophen and related methods and uses thereof
|
KR101094231B1
(ko)
|
2008-02-18 |
2011-12-14 |
하나제약 주식회사 |
서방성 고형 제제 및 그의 제조방법
|
US8372432B2
(en)
|
2008-03-11 |
2013-02-12 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
CA2720108C
(en)
|
2008-03-11 |
2016-06-07 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
|
WO2009124210A1
(en)
|
2008-04-02 |
2009-10-08 |
Cytochroma Inc. |
Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
|
US20100081861A1
(en)
*
|
2008-04-24 |
2010-04-01 |
Searete Llc |
Computational System and Method for Memory Modification
|
US20090271009A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination treatment modification methods and systems
|
US20100100036A1
(en)
*
|
2008-04-24 |
2010-04-22 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational System and Method for Memory Modification
|
US20100081860A1
(en)
*
|
2008-04-24 |
2010-04-01 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational System and Method for Memory Modification
|
US20090312595A1
(en)
*
|
2008-04-24 |
2009-12-17 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
System and method for memory modification
|
US20100125561A1
(en)
*
|
2008-04-24 |
2010-05-20 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US9064036B2
(en)
*
|
2008-04-24 |
2015-06-23 |
The Invention Science Fund I, Llc |
Methods and systems for monitoring bioactive agent use
|
US20090271347A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring bioactive agent use
|
US8930208B2
(en)
*
|
2008-04-24 |
2015-01-06 |
The Invention Science Fund I, Llc |
Methods and systems for detecting a bioactive agent effect
|
US20090271122A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US8876688B2
(en)
*
|
2008-04-24 |
2014-11-04 |
The Invention Science Fund I, Llc |
Combination treatment modification methods and systems
|
US9649469B2
(en)
*
|
2008-04-24 |
2017-05-16 |
The Invention Science Fund I Llc |
Methods and systems for presenting a combination treatment
|
US9662391B2
(en)
*
|
2008-04-24 |
2017-05-30 |
The Invention Science Fund I Llc |
Side effect ameliorating combination therapeutic products and systems
|
US20100076249A1
(en)
*
|
2008-04-24 |
2010-03-25 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090270694A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US9026369B2
(en)
*
|
2008-04-24 |
2015-05-05 |
The Invention Science Fund I, Llc |
Methods and systems for presenting a combination treatment
|
US9560967B2
(en)
*
|
2008-04-24 |
2017-02-07 |
The Invention Science Fund I Llc |
Systems and apparatus for measuring a bioactive agent effect
|
US20100041964A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring and modifying a combination treatment
|
US9282927B2
(en)
*
|
2008-04-24 |
2016-03-15 |
Invention Science Fund I, Llc |
Methods and systems for modifying bioactive agent use
|
US20090312668A1
(en)
*
|
2008-04-24 |
2009-12-17 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100042578A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20100130811A1
(en)
*
|
2008-04-24 |
2010-05-27 |
Searete Llc |
Computational system and method for memory modification
|
US20100069724A1
(en)
*
|
2008-04-24 |
2010-03-18 |
Searete Llc |
Computational system and method for memory modification
|
US9239906B2
(en)
*
|
2008-04-24 |
2016-01-19 |
The Invention Science Fund I, Llc |
Combination treatment selection methods and systems
|
US20100022820A1
(en)
*
|
2008-04-24 |
2010-01-28 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US9449150B2
(en)
*
|
2008-04-24 |
2016-09-20 |
The Invention Science Fund I, Llc |
Combination treatment selection methods and systems
|
US20090269329A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination Therapeutic products and systems
|
US20100017001A1
(en)
*
|
2008-04-24 |
2010-01-21 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090271375A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Combination treatment selection methods and systems
|
US20100041958A1
(en)
*
|
2008-04-24 |
2010-02-18 |
Searete Llc |
Computational system and method for memory modification
|
US20100004762A1
(en)
*
|
2008-04-24 |
2010-01-07 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Computational system and method for memory modification
|
US20090270688A1
(en)
*
|
2008-04-24 |
2009-10-29 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for presenting a combination treatment
|
US20100063368A1
(en)
*
|
2008-04-24 |
2010-03-11 |
Searete Llc, A Limited Liability Corporation |
Computational system and method for memory modification
|
US20100280332A1
(en)
*
|
2008-04-24 |
2010-11-04 |
Searete Llc, A Limited Liability Corporation Of The State Of Delaware |
Methods and systems for monitoring bioactive agent use
|
AU2009243681B2
(en)
|
2008-05-09 |
2013-12-19 |
Grunenthal Gmbh |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
US20090291975A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Warren Stern |
Dual opioid pain therapy
|
MY150600A
(en)
*
|
2008-07-07 |
2014-01-30 |
Euro Celtique Sa |
Use of opioid antagonists for treating urinary retention
|
US20100260844A1
(en)
|
2008-11-03 |
2010-10-14 |
Scicinski Jan J |
Oral pharmaceutical dosage forms
|
WO2010089132A1
(en)
|
2009-02-06 |
2010-08-12 |
Egalet A/S |
Immediate release composition resistant to abuse by intake of alcohol
|
US20120065221A1
(en)
|
2009-02-26 |
2012-03-15 |
Theraquest Biosciences, Inc. |
Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
|
PT2405915T
(pt)
|
2009-03-10 |
2019-01-29 |
Euro Celtique Sa |
Composições farmacêuticas de libertação imediata compreendendo oxicodona e naloxona
|
US8811578B2
(en)
*
|
2009-03-23 |
2014-08-19 |
Telemanager Technologies, Inc. |
System and method for providing local interactive voice response services
|
EP2445487A2
(en)
|
2009-06-24 |
2012-05-02 |
Egalet Ltd. |
Controlled release formulations
|
CA2767576C
(en)
|
2009-07-08 |
2020-03-10 |
Charleston Laboratories Inc. |
Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
|
PL2456427T3
(pl)
|
2009-07-22 |
2015-07-31 |
Gruenenthal Gmbh |
Wytłaczana na gorąco postać dawki o kontrolowanym uwalnianiu
|
EP2997965B1
(en)
|
2009-07-22 |
2019-01-02 |
Grünenthal GmbH |
Tamper-resistant dosage form for oxidation-sensitive opioids
|
US20110046173A1
(en)
*
|
2009-08-24 |
2011-02-24 |
Warren Charles Stern |
Combination analgesic opioid pain therapy
|
EP2473195A4
(en)
*
|
2009-08-31 |
2013-01-16 |
Depomed Inc |
PHARMACEUTICAL MAGNETIC RELEASE COMPOSITIONS FOR IMMEDIATE AND EXTENDED RELEASE OF ACETAMINOPHES
|
CA2775890C
(en)
*
|
2009-09-30 |
2016-06-21 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for deterring abuse
|
US20110104272A1
(en)
*
|
2009-11-05 |
2011-05-05 |
Depomed, Inc. |
Gastric retentive extended-release dosage forms comprising combinations of acetaminophen and phenylephrine
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
US9198861B2
(en)
|
2009-12-22 |
2015-12-01 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
US8597681B2
(en)
|
2009-12-22 |
2013-12-03 |
Mallinckrodt Llc |
Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
|
ES2606227T3
(es)
*
|
2010-02-03 |
2017-03-23 |
Grünenthal GmbH |
Preparación de una composición farmacéutica en polvo mediante una extrusora
|
EA029077B1
(ru)
*
|
2010-03-09 |
2018-02-28 |
Алкермес Фарма Айэленд Лимитед |
Устойчивая к спирту фармацевтическая лекарственная форма
|
CN103037902A
(zh)
|
2010-03-29 |
2013-04-10 |
赛特克罗公司 |
用于降低甲状旁腺水平的方法和组合物
|
CA2798702A1
(en)
|
2010-05-11 |
2011-11-17 |
Cima Labs Inc. |
Alcoholresistant metoprolol-containing extended-release oral dosage forms
|
BR112013000190A2
(pt)
|
2010-07-06 |
2017-11-07 |
Gruenenthal Gmbh |
formas de dosagem de retenção gástrica compreendendo um análogo de gaba e um opioide
|
TWI516286B
(zh)
|
2010-09-02 |
2016-01-11 |
歌林達股份有限公司 |
含陰離子聚合物之抗破碎劑型
|
MX2013002377A
(es)
|
2010-09-02 |
2013-04-29 |
Gruenenthal Gmbh |
Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
|
ES2444591T3
(es)
|
2010-10-28 |
2014-02-25 |
Acino Pharma Ag |
Medicamento con el principio activo hidromorfona con estabilidad al almacenamiento mejorada
|
SG191288A1
(en)
|
2010-12-22 |
2013-07-31 |
Purdue Pharma Lp |
Encased tamper resistant controlled release dosage forms
|
ES2581323T3
(es)
|
2010-12-23 |
2016-09-05 |
Purdue Pharma Lp |
Formas de dosificación oral sólida resistentes a alteraciones
|
US20140141090A1
(en)
|
2011-02-02 |
2014-05-22 |
Edward S. Wilson |
Pharmaceutical Composition Comprising Opioid Agonist And Sequestered Antagonist
|
US10905652B2
(en)
|
2011-03-23 |
2021-02-02 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US10292937B2
(en)
|
2011-03-23 |
2019-05-21 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
SG193587A1
(en)
|
2011-03-23 |
2013-10-30 |
Ironshore Pharmaceuticals & Dev Inc |
Methods and compositions for treatment of attention deficit disorder
|
US8916588B2
(en)
|
2011-03-23 |
2014-12-23 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods for treatment of attention deficit hyperactivity disorder
|
US8927010B2
(en)
|
2011-03-23 |
2015-01-06 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9603809B2
(en)
|
2011-03-23 |
2017-03-28 |
Ironshore Pharmaceuticals & Development, Inc. |
Methods of treatment of attention deficit hyperactivity disorder
|
US11241391B2
(en)
|
2011-03-23 |
2022-02-08 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9498447B2
(en)
|
2011-03-23 |
2016-11-22 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9119809B2
(en)
|
2011-03-23 |
2015-09-01 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US9283214B2
(en)
|
2011-03-23 |
2016-03-15 |
Ironshore Pharmaceuticals & Development, Inc. |
Compositions for treatment of attention deficit hyperactivity disorder
|
US8858963B1
(en)
|
2011-05-17 |
2014-10-14 |
Mallinckrodt Llc |
Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8658631B1
(en)
|
2011-05-17 |
2014-02-25 |
Mallinckrodt Llc |
Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
|
US8741885B1
(en)
|
2011-05-17 |
2014-06-03 |
Mallinckrodt Llc |
Gastric retentive extended release pharmaceutical compositions
|
WO2013000578A1
(en)
*
|
2011-06-30 |
2013-01-03 |
Develco Pharma Schweiz Ag |
Controlled release oral dosage form comprising oxycodone
|
LT2736495T
(lt)
|
2011-07-29 |
2017-11-10 |
Grünenthal GmbH |
Sugadinimui atspari tabletė, pasižyminti greitu vaisto atpalaidavimu
|
BR112014001091A2
(pt)
|
2011-07-29 |
2017-02-14 |
Gruenenthal Gmbh |
comprimido resistente à adulteração que fornece liberação imediata do fármaco
|
BR112014019988A8
(pt)
|
2012-02-28 |
2017-07-11 |
Gruenenthal Gmbh |
Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
|
AU2013204592A1
(en)
*
|
2012-04-09 |
2013-10-24 |
QRxPharma Ltd. |
Controlled release formulations of opioids
|
AR092820A1
(es)
|
2012-04-17 |
2015-05-06 |
Purdue Pharma Lp |
Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides, unidad de dosis, kit
|
AR090695A1
(es)
|
2012-04-18 |
2014-12-03 |
Gruenenthal Gmbh |
Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
KR20150059167A
(ko)
|
2012-07-06 |
2015-05-29 |
에갈렛 리미티드 |
제어된 방출을 위한 남용 제지 약학적 조성물
|
PL2872121T3
(pl)
|
2012-07-12 |
2019-02-28 |
SpecGx LLC |
Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
|
EP3446685A1
(en)
|
2012-11-30 |
2019-02-27 |
Acura Pharmaceuticals, Inc. |
Self-regulated release of active pharmaceutical ingredient
|
US9149533B2
(en)
|
2013-02-05 |
2015-10-06 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
EP2983468A4
(en)
|
2013-03-15 |
2016-09-07 |
Durect Corp |
COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
|
KR101847947B1
(ko)
|
2013-03-15 |
2018-05-28 |
옵코 아이피 홀딩스 Ⅱ 인코포레이티드 |
안정화되고 변형된 비타민 d 방출 제형
|
CA2907950A1
(en)
|
2013-05-29 |
2014-12-04 |
Grunenthal Gmbh |
Tamper-resistant dosage form containing one or more particles
|
JP6466417B2
(ja)
|
2013-05-29 |
2019-02-06 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
二峰性放出プロファイルを有する改変防止(tamper−resistant)剤形
|
MX368846B
(es)
|
2013-07-12 |
2019-10-18 |
Gruenenthal Gmbh |
Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
|
MY183489A
(en)
|
2013-07-23 |
2021-02-22 |
Euro Celtique Sa |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
WO2015023675A2
(en)
|
2013-08-12 |
2015-02-19 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded immediate release abuse deterrent pill
|
US20150118300A1
(en)
|
2013-10-31 |
2015-04-30 |
Cima Labs Inc. |
Immediate Release Abuse-Deterrent Granulated Dosage Forms
|
CA2931553C
(en)
|
2013-11-26 |
2022-01-18 |
Grunenthal Gmbh |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
US9492444B2
(en)
|
2013-12-17 |
2016-11-15 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
US10172797B2
(en)
|
2013-12-17 |
2019-01-08 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extruded extended release abuse deterrent pill
|
EP3122336A4
(en)
|
2014-03-26 |
2017-10-25 |
Sun Pharma Advanced Research Company Ltd |
Abuse deterrent immediate release biphasic matrix solid dosage form
|
CA2947786A1
(en)
|
2014-05-12 |
2015-11-19 |
Grunenthal Gmbh |
Tamper resistant immediate release capsule formulation comprising tapentadol
|
EP3148512A1
(en)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Multiparticles safeguarded against ethanolic dose-dumping
|
TW202136296A
(zh)
|
2014-06-27 |
2021-10-01 |
美商C2N醫療診斷有限責任公司 |
人類化抗-tau抗體
|
US9707184B2
(en)
|
2014-07-17 |
2017-07-18 |
Pharmaceutical Manufacturing Research Services, Inc. |
Immediate release abuse deterrent liquid fill dosage form
|
WO2016020508A2
(en)
|
2014-08-07 |
2016-02-11 |
Opko Ireland Global Holdings Ltd. |
Adjunctive therapy with 25-hydroxyvitamin d
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
US20160106737A1
(en)
|
2014-10-20 |
2016-04-21 |
Pharmaceutical Manufacturing Research Services, Inc. |
Extended Release Abuse Deterrent Liquid Fill Dosage Form
|
CA2936748C
(en)
|
2014-10-31 |
2017-08-08 |
Purdue Pharma |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3285745A1
(en)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Tamper-resistant dosage form with immediate release and resistance against solvent extraction
|
US11103581B2
(en)
|
2015-08-31 |
2021-08-31 |
Acura Pharmaceuticals, Inc. |
Methods and compositions for self-regulated release of active pharmaceutical ingredient
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
US9943513B1
(en)
|
2015-10-07 |
2018-04-17 |
Banner Life Sciences Llc |
Opioid abuse deterrent dosage forms
|
WO2017152130A1
(en)
|
2016-03-04 |
2017-09-08 |
Charleston Laboratories, Inc. |
Pharmaceutical compositions
|
CA3018019A1
(en)
|
2016-03-28 |
2017-10-26 |
Opko Ireland Global Holdings, Limited |
Methods of vitamin d treatment
|
US10335405B1
(en)
|
2016-05-04 |
2019-07-02 |
Patheon Softgels, Inc. |
Non-burst releasing pharmaceutical composition
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|
US10335375B2
(en)
|
2017-05-30 |
2019-07-02 |
Patheon Softgels, Inc. |
Anti-overingestion abuse deterrent compositions
|
EP3703724A1
(en)
|
2017-11-02 |
2020-09-09 |
NatureCeuticals Sdn. Bhd. |
Extract of orthosiphon stamineus, formulations, and uses thereof
|
US10722473B2
(en)
|
2018-11-19 |
2020-07-28 |
Purdue Pharma L.P. |
Methods and compositions particularly for treatment of attention deficit disorder
|
EP3965733A4
(en)
|
2019-05-07 |
2023-01-11 |
Clexio Biosciences Ltd. |
ABUSE DETERRENT DOSAGE FORMS CONTAINING ESKETAMINE
|
WO2021146215A1
(en)
|
2020-01-13 |
2021-07-22 |
Durect Corporation |
Sustained release drug delivery systems with reduced impurities and related methods
|
CN115702888A
(zh)
*
|
2021-08-13 |
2023-02-17 |
合肥立方制药股份有限公司 |
一种盐酸羟考酮渗透泵缓释片及其制备方法
|